🇺🇸 FDA
Patent

US 10927378

Compound and method for treating myotonic dystrophy

granted A61PA61P21/00

Quick answer

US patent 10927378 (Compound and method for treating myotonic dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61P, A61P21/00